| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $121,163,908 | 31 | 100 |
| JEFFS ROGER | director | 0 | $0 | 2 | $141,656 | $-141,656 |
| Mahony Susan | director | 0 | $0 | 2 | $145,017 | $-145,017 |
| Maizel Ari | Chief Commercial Officer | 0 | $0 | 2 | $2.75M | $-2.75M |
| Saad Mark E | director | 0 | $0 | 1 | $5.18M | $-5.18M |
| Coleman Mark | director | 0 | $0 | 5 | $8.21M | $-8.21M |
| Jacobson Mark L. | Chief Operating Officer | 0 | $0 | 4 | $8.9M | $-8.9M |
| Pizzie Nick | Chief Financial Officer | 0 | $0 | 2 | $10.18M | $-10.18M |
| TABUTEAU HERRIOT | Chief Executive Officer | 0 | $0 | 14 | $97.8M | $-97.8M |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials …
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $121.16M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $272,797 and sold $48.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,575 shares for transaction amount of $200,466 was made by Coleman Mark (director) on 2025‑09‑08.
| 2026-09-03 | Sale | Jacobson Mark L. | Chief Operating Officer | 10,000 0.0195% | $208.65 | $2.09M | -15.67% | |
| 2026-08-06 | Sale | TABUTEAU HERRIOT | Chief Executive Officer | 4,660 0.0092% | $213.95 | $997,007 | -5.41% | |
| 2026-08-05 | Sale | TABUTEAU HERRIOT | Chief Executive Officer | 45,004 0.0871% | $212.01 | $9.54M | -6.50% | |
| 2026-07-01 | Sale | TABUTEAU HERRIOT | Chief Executive Officer | 49,666 0.0947% | $240.25 | $11.93M | -13.65% | |
| 2026-06-11 | Sale | JEFFS ROGER | director | 286 0.0006% | $249.12 | $71,248 | -16.82% | |
| 2026-06-10 | Sale | JEFFS ROGER | director | 286 0.0006% | $246.18 | $70,407 | -14.30% | |
| 2026-06-10 | Sale | Coleman Mark | director | 643 0.0013% | $249.00 | $160,107 | -14.30% | |
| 2026-06-10 | Sale | Mahony Susan | director | 300 0.0006% | $246.18 | $73,854 | -14.30% | |
| 2026-06-09 | Sale | Pizzie Nick | Chief Financial Officer | 33,000 0.0655% | $240.09 | $7.92M | -13.88% | |
| 2026-06-09 | Sale | TABUTEAU HERRIOT | Chief Executive Officer | 49,670 0.0989% | $241.01 | $11.97M | -13.88% | |
| 2026-06-09 | Sale | Mahony Susan | director | 300 0.0006% | $237.21 | $71,163 | -13.88% | |
| 2026-06-02 | Sale | Coleman Mark | director | 5,537 0.0104% | $223.39 | $1.24M | -4.24% | |
| 2026-06-01 | Sale | Coleman Mark | director | 6,000 0.0117% | $230.30 | $1.38M | -7.58% | |
| 2026-05-29 | Sale | Coleman Mark | director | 6,000 0.0116% | $233.46 | $1.4M | -9.22% | |
| 2026-05-05 | Sale | Jacobson Mark L. | Chief Operating Officer | 233 0.0005% | $228.18 | $53,166 | -2.93% | |
| 2026-05-04 | Sale | Jacobson Mark L. | Chief Operating Officer | 4,517 0.009% | $227.94 | $1.03M | -3.18% | |
| 2026-04-22 | Sale | Maizel Ari | Chief Commercial Officer | 7,500 0.0143% | $182.42 | $1.37M | +15.74% | |
| 2026-02-26 | Sale | Coleman Mark | director | 25,000 0.049% | $161.11 | $4.03M | +27.32% | |
| 2026-02-26 | Sale | Jacobson Mark L. | Chief Operating Officer | 35,378 0.0696% | $161.88 | $5.73M | +27.32% | |
| 2026-02-02 | Sale | TABUTEAU HERRIOT | Chief Executive Officer | 32,410 0.0642% | $185.60 | $6.02M | +10.14% |
| JEFFS ROGER | director | 58367 0.1114% | $8.15M | 1 | 10 | +3.44% |
| Pizzie Nick | Chief Financial Officer | 42867 0.0818% | $5.98M | 6 | 4 | +84.72% |
| Coleman Mark | director | 30389 0.058% | $4.24M | 8 | 11 | +49.61% |
| Saad Mark E | director | 10002 0.0191% | $1.4M | 2 | 3 | +23.86% |
| Kaye Randall | Chief Medical Officer | 6022 0.0115% | $840,731.42 | 1 | 0 | <0.0001% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 229 | +60.58% | 6M | +16.06% |
| Decreased Positions | 164 | -43.39% | 6M | -15.35% |
| New Positions | 86 | New | 2M | New |
| Sold Out Positions | 36 | Sold Out | 2M | Sold Out |
| Total Postitions | 443 | +17.2% | 38M | +0.71% |
| Vanguard Group Inc | $747,040.00 | 8.36% | 4.18M | +235,626 | +5.97% | 2025-09-30 |
| Blackrock, Inc. | $677,401.00 | 7.58% | 3.79M | -44,061 | -1.15% | 2025-09-30 |
| Wellington Management Group Llp | $238,473.00 | 2.67% | 1.33M | +609,516 | +84.07% | 2025-09-30 |
| Rtw Investments, Lp | $199,933.00 | 2.24% | 1.12M | -398,020 | -26.24% | 2025-09-30 |
| Macquarie Group Ltd | $193,796.00 | 2.17% | 1.08M | -53,212 | -4.68% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $185,382.00 | 2.08% | 1.04M | +424,705 | +69.31% | 2025-09-30 |
| Geode Capital Management, Llc | $178,279.00 | 2% | 997,700 | +8,247 | +0.83% | 2025-09-30 |
| Invesco Ltd. | $177,003.00 | 1.98% | 990,557 | +419,008 | +73.31% | 2025-09-30 |
| State Street Corp | $168,498.00 | 1.89% | 942,960 | -15,543 | -1.62% | 2025-09-30 |
| Fmr Llc | $165,803.00 | 1.86% | 927,883 | -48,847 | -5% | 2025-09-30 |